BIOCQ (Biocept) Forward Dividend Yield %: 0.00% (As of Jun. 28, 2026)


BIOCQ Biocept Inc BIOCQ
16 GF Score
Price $0.00
View Full Analysis

What is Biocept Forward Dividend Yield %?

Biocept BIOCQ 16 Forward Dividend Yield % is 0.00% as of Jun. 28, 2026. GuruFocus rates BIOCQ with a GF Score™ of 16/100.

As of today (2026-06-28), the Forward Annual Dividend Yield of Biocept is 0.00%.

As of today (2026-06-28), the Trailing Annual Dividend Yield of Biocept is 0.00%.

BIOCQ's Forward Dividend Yield % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.875
* Ranked among companies with meaningful Forward Dividend Yield % only.

Biocept's Dividends per Share for the three months ended in Jun. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Biocept  (OTCPK:BIOCQ) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Biocept Forward Dividend Yield % Related Terms

BIOCQ vs IDTA, DIGP, ABMC: Forward Dividend Yield % Comparison

For the Diagnostics & Research subindustry, Biocept's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocept Forward Dividend Yield % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Biocept's Forward Dividend Yield % falls into.


BIOCQ
16GF Score
Biocept Inc BIOCQ
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocept Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Biocept (BIOCQ) has a Forward Dividend Yield % of 0.00% as of Jun. 28, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Biocept and its competitors.
Is Biocept's Forward Dividend Yield % too high?
Biocept's current Forward Dividend Yield % is 0.00%. Overall, Biocept has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Biocept's Forward Dividend Yield % compare to IDTA and DIGP?
Biocept's Forward Dividend Yield % of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. The industry median Forward Dividend Yield % is 1.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Diagnostics & Research company?
The median Forward Dividend Yield % among Medical Diagnostics & Research companies is 1.88, based on 62 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Biocept and its competitors. For the Medical Diagnostics & Research industry, the median Forward Dividend Yield % is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocept's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocept stock overvalued right now?
Biocept (BIOCQ) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Biocept's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Biocept (BIOCQ), the current Forward Dividend Yield % is 0.00% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biocept Business Description

Address 9955 Mesa Rim Road, San Diego, CA, USA, 92121
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
16GF Score

Get the complete analysis for BIOCQ

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price